A 45-year-old with a thyroid nodule and a suspicious lymph node
A 45-year-old woman is referred with a 2.5 cm right thyroid nodule found incidentally. She has no compressive symptoms and no family history of thyroid cancer. Ultrasound shows a solid, hypoechoic nodule with microcalcifications and irregular margins (TIRADS 5), and a 1.2 cm right level III lymph node with loss of the fatty hilum and microcalcifications. FNA of the nodule is Bethesda VI (papillary thyroid carcinoma); FNA of the node is positive for metastatic papillary carcinoma. Vocal cords are mobile bilaterally. Calcium and PTH are normal. She is euthyroid. She asks whether she can have a 'keyhole' operation and whether she needs radioiodine.
1. What is the extent of surgery you would recommend, and how do the nodal findings and her wishes influence it?
Read the worked answer
Staging and risk
- Papillary thyroid carcinoma, 2.5 cm, with a cytologically proven level III node = cN1b. This is at least stage I by AJCC (age <55), but the nodal disease places her at intermediate risk for recurrence by ATA.
- Pre-operative staging: ultrasound of the central and lateral neck (already done), and consider cross-sectional imaging (CT neck with contrast) if bulky nodal disease or concern about level VI/VII; contrast is acceptable now because surgery is planned.
Extent of surgery
- Total thyroidectomy plus central (level VI) neck dissection is recommended, with therapeutic lateral neck dissection (levels II–V, at least III–IV) on the right because level III is proven metastatic.
- A lobectomy alone is inadequate: it leaves contralateral disease risk and does not permit radioiodine or thyroglobulin surveillance, and it does not address the nodal disease.
- Prophylactic lateral neck dissection on the contralateral side is not indicated.
Her question about 'keyhole' surgery
- Remote-access/robotic approaches are oncologically feasible in selected patients but are not standard for cN1b disease requiring lateral neck dissection; the lateral dissection is difficult to perform adequately through a remote access. Explain that a standard collar incision gives the best oncological clearance and that cosmesis can be optimised with a low, small incision.
Risks to discuss
- Recurrent laryngeal nerve injury (especially right, with level VI dissection), hypoparathyroidism (higher with total thyroidectomy + central dissection), haematoma, and scarring. Consider intraoperative nerve monitoring.
2. Post-operatively she has perioral tingling and a corrected calcium of 1.85 mmol/L on day 1. How do you manage this, and when would you consider radioiodine?
Read the worked answer
Diagnosis
- Transient post-thyroidectomy hypocalcaemia - very common after total thyroidectomy with central neck dissection. Symptoms (perioral tingling, carpopedal spasm) plus corrected calcium 1.85 mmol/L confirm it.
Management
- Check PTH (if available) and magnesium; low PTH supports hypoparathyroidism.
- IV calcium gluconate (e.g., 10–20 mL of 10% over 10–20 min, then infusion) if symptomatic or calcium <1.9 mmol/L; monitor ECG.
- Oral calcium carbonate (e.g., 1–2 g elemental calcium three times daily) plus calcitriol (0.25–0.5 µg twice daily) once stable.
- Recheck calcium 6–12 hourly; aim for low-normal to avoid hypercalciuria.
- Avoid over-treatment; most patients recover parathyroid function within weeks to months. Plan to wean oral supplements guided by calcium and PTH.
- Document in the discharge letter and arrange early follow-up.
Radioiodine
- Indication depends on risk stratification after total thyroidectomy and neck dissection: intermediate-risk disease (microscopic extrathyroidal extension, or nodal metastases) may be offered remnant ablation with radioiodine (30–150 mCi) to reduce recurrence, though the benefit in low-volume nodal disease is debated.
- Timing: usually 4–12 weeks post-operatively, after TSH stimulation (withdrawal or recombinant TSH), once the wound has healed and calcium is stable.
- Not indicated in low-risk disease with complete resection and no aggressive features.
- Discuss in a multidisciplinary thyroid MDT; counsel about salivary, lacrimal, and fertility considerations, and pregnancy avoidance for ~6–12 months.
Surveillance
- Thyroglobulin and anti-thyroglobulin antibodies, neck ultrasound at 6–12 months, and lifelong levothyroxine with TSH targeted (suppressed or low-normal depending on risk).